Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cinnamic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 known ✓ | O15379 | 2/20 | 0.95 |
| ▸ | HDAC4 known ✓ | P56524 | 2/20 | 0.95 |
| ▸ | HDAC1 known ✓ | Q13547 | 2/20 | 0.95 |
| ▸ | HDAC2 known ✓ | Q92769 | 2/20 | 0.95 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 2/20 | 0.95 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 2/20 | 0.95 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 1/20 | 0.95 |
| ▸ | HDAC10 known ✓ | Q969S8 | 1/20 | 0.95 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 1/20 | 0.95 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 1/20 | 0.95 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 1/20 | 0.95 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.64 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.64 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.64 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.64 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.64 |
| ▸ | MAOB known ✓ | P27338 | 2/20 | 0.61 |
| ▸ | BCHE known ✓ | P06276 | 1/20 | 0.61 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.61 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cinnamic Acid SCHEMBL4238400 | 1.00 | HCAR2 (0.95) | HCAR2HDAC3HDAC4HDAC1HDAC2 | |
| Cinnamic Acid SCHEMBL29989544 | 0.97 | HCAR2 (1.00) | HCAR2HDAC3HDAC4HDAC1HDAC2 | |
| Cinnamic Acid SCHEMBL1332 | 0.97 | HCAR2 (1.00) | HCAR2HDAC3HDAC4HDAC1HDAC2 | |
| Cinnamic Acid SCHEMBL1333 | 0.97 | HCAR2 (1.00) | HCAR2HDAC3HDAC4HDAC1HDAC2 | |
| Cinnamic Acid SCHEMBL3406486 | 0.97 | HCAR2 (1.00) | HCAR2HDAC3HDAC4HDAC1HDAC2 | |
| Cinnamic Acid SCHEMBL653827 | 0.97 | HCAR2 (1.00) | HCAR2HDAC3HDAC4HDAC1HDAC2 | |
| Cinnamic Acid SCHEMBL653828 | 0.97 | HCAR2 (1.00) | HCAR2HDAC3HDAC4HDAC1HDAC2 | |
| Cinnamic Acid SCHEMBL1706935 | 0.97 | HCAR2 (1.00) | HCAR2HDAC3HDAC4HDAC1HDAC2 | |
| Cinnamic Acid SCHEMBL50466 | 0.97 | HCAR2 (1.00) | HCAR2HDAC3HDAC4HDAC1HDAC2 | |
| Cinnamic Acid SCHEMBL6738817 | 0.95 | HCAR2 (0.95) | HCAR2HDAC3HDAC4HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3943137-A | ANTITUMOR | UNIVERSITY OF KANSAS ENDOWMENT ASSOCIATION (US) | 1976-03-09 | — | — | US | claimed |
| JP-62174744-A | — | — | None | — | — | JP | disclosed |
| CN-119119435-A | Trans-cinnamic acid end-capped polyarylate, preparation method and application | 中国科学院大连化学物理研究所 | 2024-12-13 | — | — | CN | disclosed |
| CN-119101220-A | Phosphorus-containing high-refractive-index optical polyarylester and preparation method thereof | 中国科学院大连化学物理研究所 | 2024-12-10 | — | — | CN | disclosed |
| CN-110914234-B | Amine compound for inhibiting SSAO/VAP-1 and application thereof in medicine | 广东东阳光药业有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-113105408-B | Novel asymmetric catalytic nucleophilic fluorine heterocyclic reaction system and application thereof in chiral unnatural amino acid module synthesis | 深圳市图微安创科技开发有限公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-113105408-A | Novel asymmetric catalytic nucleophilic fluorine heterocyclic reaction system and application thereof in chiral unnatural amino acid module synthesis | 深圳市图微安创科技开发有限公司 | 2021-07-13 | — | — | CN | disclosed |
| EP-1882684-B1 | PYRROLIDINE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-12-10 | — | — | EP | disclosed |
| US-8354392-B2 | Drug-introduced photo-crosslinked hyaluronic acid derived gel | SEIKAGAKU CORPORATION (JP) | 2013-01-15 | — | — | US | disclosed |
| US-20120035224-A1 | Betulin derived compounds as anti-feedants for plant pests | VALTION TEKNILLINEN TUTKIMUSKESKUS (FI) | 2012-02-09 | — | — | US | disclosed |
| CN-1668578-A | Flavourant compounds | GIVAUDAN SA (CH) | 2005-09-14 | — | — | CN | disclosed |
| US-20040158030-A1 | Diamine, acid dianhydride, polymide composition having reactive group obtained therefrom, and processes for producing these | KANEKA CORPORATION (JP) | 2004-08-12 | — | — | US | disclosed |
| US-6103794-A | POWDER COATING COMPOSITION COMPRISING FILM-FORMING BINDER, STABILIZER; DISCOLORATION INHIBITION DURING CURING | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2000-08-15 | — | — | US | disclosed |
| US-6060545-A | COMPOSITIONS COMPRISING ORGANIC MATERIAL SUBJECT TO OXIDATIVE, THERMAL OR LIGHT-INDUCED DEGRADATION, AT LEAST ONE BISPHENOL ESTER DERIVATIVE AND CALCIUM LACTATE AND/OR CALCIUM STEARYL-2 LACTYLATE | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2000-05-09 | — | — | US | disclosed |
| US-5807942-A | ADDITION POLYMERIZABLE MONOMER UNIT IS ATTACHED TO ENZYME, ANTIBODY, ETC. AND RESULTING COMPOUND IS POLYMERIZED THROUGH DOUBLE BOND WITH ANOTHER MODIFIED ENZYME OR ANTIBODY OR WITH A MONOMER SUCH AS METHACRYLAMIDE, USED IN IMMUNOASSAY | NOF CORPORATION (JP) | 1998-09-15 | — | — | US | disclosed |
| EP-0719291-B1 | NOVEL FUNCTIONALIZED ISOOLEFIN/PARA-ALKYLSTYRENE COPOLYMERS | EXXON RESEARCH ENGINEERING CO (US) | 1998-05-20 | — | — | EP | disclosed |
| EP-0719291-A4 | NOVEL FUNCTIONALIZED ISOOLEFIN/PARA-ALKYLSTYRENE COPOLYMERS | EXXON RESEARCH ENGINEERING CO (US) | 1996-08-21 | — | — | EP | disclosed |
| EP-0719291-A1 | NOVEL FUNCTIONALIZED ISOOLEFIN/PARA-ALKYLSTYRENE COPOLYMERS | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1996-07-03 | — | — | EP | disclosed |
| WO-1995007945-A1 | NOVEL FUNCTIONALIZED ISOOLEFIN/PARA-ALKYLSTYRENE COPOLYMERS | EXXON RESEARCH & ENGINEERING COMPANY (US) | 1995-03-23 | — | — | WO | disclosed |
| JP-S62174744-A | PHOTOSENSITIVE IMAGE FORMING MATERIAL CAPABLE OF BEING DEVELOPED WITH AQUEOUS ALKALINE DEVELOPING SOLUTION | DAINIPPON INK & CHEM INC | 1987-07-31 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035224-A1 | Betulin derived compounds as anti-feedants for plant pests | BET1, BTF3, BROX | HDAC3 1305/4885HDAC4 1019/4885HDAC1 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.